Publication Topic

Sacks NC, Sharma A, Cyr PL, Bertiger G, Dahdal DN, Brogadir S. 2018. Real-world comparison of the effectiveness and safety of different bowel preparation agents. Clin Exp Gastroenterol 11(Aug 16):289–299; doi: 10.2147/CEG.S171861. PMID: 30555250.

Suh M, Wikoff D, Harvey S, Mittal L, Lipworth L, Goodman M, Goodmanson A, Ring C, Rohr A, Proctor D. Hexavalent chromium and stomach cancer: A systematic review and meta-analysis. Presented at Joint Annual Meeting of International Society of Exposure Science and International Society for Environmental Epidemiology (ISES-ISEE 2018), Ottawa, Canada, August 2018.

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016. PMID: 29684431.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.

Sacks NC, Sharma A, Cyr PL, Bertiger G, Dahdal DN, Brogadir S. 2018. Real-world evidence comparison of the efficacy and safety of different bowel preparation agents in a high-risk population. Gastroenterol 154(6) S632-S633; doi: 10.1016/S0016-5085(18)32266-2.

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012. PMID: 29673891.

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM,  Flanders SC, Barlev A, et al. 2018. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States. Cancer 124(10):2104-2114; doi: 10.1002/cncr.31299. PMID: 29505670.

Fryzek J, Reichert H, Summers N, Townes L, Deuson R, Alexander DD, Vanderpuye-Orgle J. 2018. Indirect treatment comparison of cabazitaxel for patients with metastatic castration-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One 13(4):e0195790; doi: 10.1371/journal.pone.0195790. PMID: 29641566.

Frankenfeld CL, Hakes J, Leslie TF. All-cancer and cancer-specific mortality is associated with black race segregation in the United States: Mortality Disparities in American Communities data. American Association for Cancer Research: Poster presentation to The Science of Cancer Health Disparities, 2018.

Bylsma LC, Gillezeau C, Garawin T, Kelsh M, Fryzek J, Sangare L, Lowe KA. Prevalence of RAS and BRAF mutations in Metastatic Colorectal Cancer (mCRC) patients by tumor location. Presented at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 2018.